Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of OnabotulinumtoxinA in Migraine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects fulfilling the diagnostic criteria for migraine without or with aura of the International Headache Classification with a number of migraine days ranging from 9 to 14 days/month in the previous 3 months.~* The frequency needs to be confirmed over the 28 days before the screening visit .~* Subjects have to be in general good health, as confirmed by medical history, baseline physical examination, baseline neurological exam and vital signs.~* Females have to be postmenopausal for at least one year, surgically sterile or otherwise incapable of pregnancy, or using an acceptable method of birth control.~Exclusion Criteria:~* Previous failure of more than two adequate trials of medications from different drug classes used for migraine prophylaxis;~* Onset of migraine after age 50;~* Exclusively migraine aura without headache;~* Diagnosis of other primary or secondary headache disorders. Episodic tension-tyep headache is allowed if the patient can distinguish clearly between attack of migraine and of tension-type headache;~* Another chronic painful condition (e.g. osteoarthritis, low back pain);~* A significant medical history or medical condition of neurological, cardiovascular hepatic or renal disease;~* History of suicide attempt or suicidal ideation or of a major psychiatric disorder;~* History of drug or alcohol abuse within the past two years.~* Known hypersensitivity to botulinum toxin type A or to any of the other ingredients used to form 'Botox®'~Withdrawal criteria~• Severe side effects, diary completion insufficient for evaluation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- BOTOX (Type: EXPERIMENTAL): 155 UI of Botox were injected according to the approved PREEMPT protocol (the only FDA-approved injection pattern for chronic migraine), in 31 sites. From visit 5, the PREEMPT 'follow-the-pain' paradigm was applied in patients falling in the 'non-responder' or 'partial responder' classes after the first BoNT-A injection, with the possibility to increase the doses up to 195 UI in maximum 39 sites. The injections were every 3 months for 4 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).